Bimekizumab, a humanised monoclonal antibody, is the first and only dual inhibitor of IL-17A and IL-17F, two pro-inflammatory ...
The upcoming drugs CagriSema and retatrutide target multiple gut hormones and could cause twice as much weight loss than ...
For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor ...
Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...
Clinical Trials Arena on MSN
AiCuris reports positive Phase III pritelivir results for HSV patients
The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.
Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...
Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635 (c) (4) and were granted ...
Get all latest & breaking news on Adani Port . Watch videos, top stories and articles on Adani Port at moneycontrol.com.
Innovative Molecules GmbH, a German clinical stage biotech company focused on development of novel agents in the field of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results